CgA plasma levels, PPI therapy, and responses. (A) Relationship between CgA plasma levels and response to NGR-hTNF/R-CHOP. Baseline plasma levels of CgA of patients who achieved a CR (n = 12) and patients who did not (others, n = 16). Median CgA levels were 1.14 nM (range, 0.29-2.72 nM) and 2.10 nM (range, 0.47-5.81 nM), respectively (P = .066). (B-C) Changes in CgA plasma levels after PPI interruption. The comparison of CgA concentrations in plasma samples collected at trial registration (baseline) and before the third course (2 months) showed level reduction in some patients after PPI interruption (B), whereas the values remained stable in patients who had not received this drug (C). No differences were detected between patients achieving a CR (continued lines) or a PR (dotted lines). These analyses were performed in the 14 patients who had samples taken at 3 time points at least.